Immunology and inflammation Archives -

Sanofi and Regeneron have added another string to the bow of their immunology blockbuster Dupixent with an FDA

Dupixent claims new territory in eosinophilic oesophagitis

https://pharmaphorum.com/news/dupixent-claims-new-territory-in-eosinophilic-oesophagitis/

News

Sanofi’s R&D platform building continues with $6bn-plus IGM deal

Phil Taylor antibody, GM Biosciences, Immunology and inflammation, Oncology, partnering, Sanofi 0 Comment

Sanofi has agreed another deal to flesh out its R&D pipeline, paying IGM Biosciences $150 million upfront to

Sanofi’s R&D platform building continues with $6bn-plus IGM deal

https://pharmaphorum.com/news/sanofis-rd-platform-building-continues-with-6bn-plus-igm-deal/

News/ News/ R&D

Etrasimod data suggests Pfizer’s $6.7bn gamble on Arena will pay off

Phil Taylor Bristol-Myers Squibb, etrasimod, Immunology and inflammation, Pfizer, ulcerative colitis, Zeposia 0 Comment

It’s only been two weeks since Pfizer closed its $6.7 billion takeover of Arena Pharmaceuticals, and it already

Etrasimod data suggests Pfizer’s $6.7bn gamble on Arena will pay off

https://pharmaphorum.com/news/etrasimod-data-suggests-pfizers-6-7bn-gamble-on-arena-will-pay-off/

Boehringer Ingelheim, Biberach, Germany, February 2007

News/ News/ R&D

Boehringer’s spesolimab data raises hope for serious skin disease

Phil Taylor Boehringer Ingelheim, dermatology, Immunology and inflammation, rare disease, spesolimab 0 Comment

Fresh from being awarded a fast-track review from the FDA, Boehringer Ingelheim’s spesolimab has shown encouraging efficacy in

Boehringer’s spesolimab data raises hope for serious skin disease

https://pharmaphorum.com/news/boehringers-spesolimab-data-raises-hope-for-serious-skin-disease/

Market Access/ News/ News

FDA knocks back Takeda’s blockbuster hope TAK-721

Phil Taylor eosinophilic oesophagitis, Immunology and inflammation, pipeline, Takeda 0 Comment

Japanese drugmaker Takeda has suffered a blow to its late-stage pipeline, after the FDA rejected its marketing application

FDA knocks back Takeda’s blockbuster hope TAK-721

https://pharmaphorum.com/news/fda-knocks-back-takedas-blockbuster-hope-tak-721/

News/ News/ R&D

Blow for Novartis as ligelizumab can’t top Xolair in phase 3

Phil Taylor chronic spontaneous urticaria, fenebrutinib, Immunology and inflammation, ligelizumab, Novartis, remibrutinib, Roche, Xolair 0 Comment

Novartis’ big-selling IgE inhibitor Xolair has been a mainstay of treatment for chronic spontaneous urticaria (CSU) for many

Blow for Novartis as ligelizumab can’t top Xolair in phase 3

https://pharmaphorum.com/news/blow-for-novartis-as-ligelizumab-cant-top-xolair-in-phase-3/

News/ News/ R&D

Flush with COVID cash, Pfizer tables $6.7bn bid for Arena

Phil Taylor Arena Pharmaceuticals, Bristol-Myers Squibb, etrasimod, Immunology and inflammation, M&A, Pfizer, ulcerative colitis, Zeposia 0 Comment

Pfizer has found another use for the windfall profits it is making from it BioNTech-partnered COVID-19 vaccine, agreeing

Flush with COVID cash, Pfizer tables $6.7bn bid for Arena

https://pharmaphorum.com/news/flush-with-covid-cash-pfizer-tables-6-7bn-bid-for-arena/

Market Access/ News/ News

FDA sets Sept review date for BMS’ psoriasis drug deucravacitinib

Phil Taylor Amgen, Bristol-Myers Squibb, deucravacitinib, Immunology and inflammation, Otezla, psoriasis 0 Comment

The FDA has kicked off its review of Bristol-Myers Squibb’s psoriasis therapy deucravacitinib, setting an action date of

FDA sets Sept review date for BMS’ psoriasis drug deucravacitinib

https://pharmaphorum.com/news/fda-sets-sept-review-date-for-bms-psoriasis-drug-deucravacitinib/

News/ News/ Oncology

Strike two for Novartis’ lung cancer antibody canakinumab

Phil Taylor canakinumab, Immunology and inflammation, lung cancer, Novartis, Oncology 0 Comment

Expectations for Novartis’ canakinumab as a therapy for cancer have taken another dive, after a second phase 3

Strike two for Novartis’ lung cancer antibody canakinumab

https://pharmaphorum.com/news/strike-two-for-novartis-lung-cancer-antibody-canakinumab/

Trending

Immunology and inflammation

Login